With roughly 4,600 participants, two pivotal trials, and a regulatory clock that runs through late 2028, Ascletis has placed a substantial bet that the obesity pill market will be far more crowded and competitive by the time ASC30 reaches an FDA reviewer’s desk. The company announced this week that the first participant has been dosed in AURORA-1 and AURORA-2, its global Phase III program for the once-daily oral small molecule GLP-1 receptor agonist ASC30. That timing matters because oral semaglutide for weight management already cleared the FDA in December 2025, and Ascletis itself acknowledges ASC30 is positioned to become the second oral small molecule GLP-1 receptor agonist available in the U.S. and Europe, if approved. Entering a market against an established oral incumbent is a meaningfully different competitive posture than entering against injectables alone.
The trial architecture is straightforward but demanding. AURORA-1 enrolls adults with obesity or overweight without type 2 diabetes; AURORA-2 targets the same BMI thresholds in patients who have type 2 diabetes. Both are 72-week, randomized, double-blind, placebo-controlled studies testing three maintenance doses (20 mg, 40 mg, and 60 mg), with percentage change in body weight from baseline as the primary endpoint in each. Sites span the U.S., Europe, and Canada. Topline data are expected in the third quarter of 2028, with an NDA submission targeted by year-end 2028 and an EMA marketing authorization application to follow in early 2029. Ascletis states its current cash position funds operations into 2029, covering both planned regulatory submissions without an intervening financing round.
The Phase II profile Ascletis is carrying into Phase III includes what the company describes as a competitive weight loss signal, favorable gastrointestinal tolerability, and no observed hepatic safety signals. That last point deserves attention: hepatotoxicity concerns have shadowed some small molecule GLP-1 programs, and a clean liver signal through Phase II removes one plausible obstacle to enrollment and regulatory acceptance. The STEP UP trial showed oral semaglutide 7.2 mg achieving 20.7% mean weight loss at 72 weeks in adherent patients, setting a concrete efficacy benchmark that ASC30’s dose-ranging design will need to address credibly at the 60 mg ceiling.
Beyond the monotherapy program, Ascletis is also advancing oral fixed-dose combinations targeting GLP-1/GIP and GLP-1/GIP/amylin, positioning ASC30 as a platform anchor rather than a standalone asset. That pipeline logic only pays off if AURORA delivers on weight loss magnitude. The single number to track between now and Q3 2028 is the 60 mg arm’s percentage body weight reduction: it is the dose most likely to define whether ASC30 can differentiate from a now-entrenched oral competitor or arrive as a follower competing on convenience and tolerability alone.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
